DISSOLUTION PROFILE STUDY FOR INNOVATION ANTI-RETROVIRAL DRUG PRODUCT NIKAVIR® AND ITS FIXED COMBINATION WITH LAMIVUDINE (PHOSPHALADINE®)
Biopharmaceutical solubility was experimentally determined for innovation anti-retroviral API phosphazide (Nikavir®) which was classified as BCS Class 3 drug. Dissolution profile test for Nikavir® 200 mg and 400 mg in three media pH 1.2, 4.5, 6.8 was conducted, and equivalence for both dosages was s...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2019-01-01
|
| Series: | Разработка и регистрация лекарственных средств |
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/94 |